title: Combined chemoradiotherapy for early glottic cancer in clinical practice in Japan: analysis of 10 institutions.
abstract: OBJECTIVE
  To conduct a retrospective analysis regarding treatment strategies for early glottic cancer (GC) at ten institutions.
  
  
  METHODS
  A questionnaire-based survey was used to obtain personal and medical information on patients who started radiation therapy for T1 or T2 GC between January 2000 and December 2005.
  
  
  RESULTS
  A total of 279 patients were registered for the survey, of whom 124 patients were classified as T1a, with 65 patients as T1b and 87 patients as T2. The rates of chemoradiotherapy for T1a, T1b and T2 were 24%, 23% and 60%, respectively. A comparison of results for academic and non-academic hospitals showed statistically different rates of combination therapy for T1a (6.9% vs. 39.3%, respectively; p<0.001) and T1b (11.4% vs. 36.6%, respectively; p<0.05) but not for T2 (70.0% vs. 54.4%, respectively; p = 0.158).
  
  
  CONCLUSIONS
  In clinical practice, combined chemoradiotherapy was performed for early GC at most institutions in Tokai District, Japan.
authors.affiliation: Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan. itoh@med.nagoya-u.ac.jp
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Itoh
authors.forename: Naoki
authors.initials: N
authors.lastname: Hirasawa
authors.forename: Shinji
authors.initials: S
authors.lastname: Naganawa
authors.forename: Shunichi
authors.initials: S
authors.lastname: Ishihara
authors.forename: Kazunori
authors.initials: K
authors.lastname: Suzuki
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Koyama
authors.forename: Takayuki
authors.initials: T
authors.lastname: Murao
authors.forename: Akiko
authors.initials: A
authors.lastname: Asano
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Nomoto
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Horikawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sasaoka
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Obata
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005931:Glottis; D006801:Humans; D007564:Japan; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil; D016190:Carboplatin; D002945:Cisplatin; D005472:Fluorouracil